Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. News
  7. Summary
    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Lonza : To Manufacture aTyr Pharma's Potential Antibody Therapy For Aggressive Tumors

04/15/2021 | 12:14am EDT


© MT Newswires 2021
All news about LONZA GROUP AG
06:34aTODAY'S ANALYST RECOMMENDATIONS : Alibaba, BioNTech, Home Depot, Lowe's, Roblox...
06:20aLONZA  : AlphaValue/Baader Europe Lowers Price Target on Lonza Group
MT
01:09aLONZA  : Moderna to Ship 25 Million COVID-19 Vaccine Doses to Australia By 2022
MT
05/10LONZA GROUP LTD : Ex-dividend day for final dividend
FA
05/10LONZA GROUP LTD : Ex-dividend day for
FA
05/07LONZA  : Announces Results of the 2021 Annual General Meeting - All Motions Prop..
AQ
05/07LONZA  : Specialty Ingredients to Lift Prices of Selected Products Due to Rising..
MT
05/07LONZA  : Price Change Notification on Selected Product Portfolios
PU
05/07LONZA  : Moderna Expects No Impact of Possible Patent Waiver on COVID-19 Vaccine..
MT
05/07Switzerland Questions US Backing For Waiving COVID-19 Vaccine Patents
MT
More news
Financials
Sales 2021 4 980 M 5 488 M 5 488 M
Net income 2021 1 039 M 1 145 M 1 145 M
Net Debt 2021 1 142 M 1 258 M 1 258 M
P/E ratio 2021 40,5x
Yield 2021 0,55%
Capitalization 41 480 M 45 649 M 45 711 M
EV / Sales 2021 8,56x
EV / Sales 2022 7,71x
Nbr of Employees 16 540
Free-Float 99,6%
Chart LONZA GROUP AG
Duration : Period :
Lonza Group AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 657,53 CHF
Last Close Price 558,40 CHF
Spread / Highest target 39,1%
Spread / Average Target 17,8%
Spread / Lowest Target -7,23%
EPS Revisions
Managers and Directors
NameTitle
Pierre-Alain Ruffieux Chief Executive Officer
Rodolfo Savitzky Chief Financial Officer
Albert M. Baehny Chairman
Werner J. Bauer Independent Director
Barbara May Richmond No-Executive Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
LONZA GROUP AG-1.83%45 649
MODERNA, INC.46.15%61 305
IQVIA HOLDINGS INC.27.25%43 699
CELLTRION, INC.-26.88%31 675
SEAGEN INC.-17.34%26 272
CUREVAC N.V.15.90%21 497